BACKGROUND: In most seasons, the influenza vaccine is effective in preventing influenza, but it is not clear whether it is equally effective in preventing mild and severe cases. We designed a case-control study to compare the effectiveness of the influenza vaccine in preventing outpatient, inpatient, and severe or fatal cases of laboratory-confirmed influenza. METHODS: Hospitalized patients (n = 691) with laboratory-confirmed influenza in the 2010-2011 season recruited in 29 Spanish hospitals were individually matched by age, admission/visit date, and province with an outpatient with laboratory-confirmed influenza and an outpatient control. Severe cases were considered those patients admitted to intensive care units or who died in the hospital (n = 177). We compared the influenza vaccine status of controls and outpatient cases, inpatient cases, and severe cases using conditional logistic regression adjusted for potential confounding factors. Severe and nonsevere inpatient influenza cases were compared using unconditional logistic regression. Vaccine effectiveness was (1 - odds ratio) × 100. RESULTS: Vaccine effectiveness was 75% (adjusted odds ratio [AOR], 0.25; 95% confidence interval [CI], .16-.39) in preventing influenza outpatient cases, 60% (AOR, 0.40; 95% CI, .25-.63) in preventing influenza-associated hospitalizations, and 89% (AOR, 0.11; 95% CI, .04-.37) in preventing severe cases. In inpatients, influenza vaccination was associated with a lower risk of severe influenza (AOR, 0.42; 95% CI, .22-.80). CONCLUSIONS: Influenza vaccination prevented influenza cases and hospitalizations and was associated with a better prognosis in inpatients with influenza. The combined effect of these 2 mechanisms would explain the high effectiveness of the vaccine in preventing severe cases due to influenza.
BACKGROUND: In most seasons, the influenza vaccine is effective in preventing influenza, but it is not clear whether it is equally effective in preventing mild and severe cases. We designed a case-control study to compare the effectiveness of the influenza vaccine in preventing outpatient, inpatient, and severe or fatal cases of laboratory-confirmed influenza. METHODS: Hospitalized patients (n = 691) with laboratory-confirmed influenza in the 2010-2011 season recruited in 29 Spanish hospitals were individually matched by age, admission/visit date, and province with an outpatient with laboratory-confirmed influenza and an outpatient control. Severe cases were considered those patients admitted to intensive care units or who died in the hospital (n = 177). We compared the influenza vaccine status of controls and outpatient cases, inpatient cases, and severe cases using conditional logistic regression adjusted for potential confounding factors. Severe and nonsevere inpatient influenza cases were compared using unconditional logistic regression. Vaccine effectiveness was (1 - odds ratio) × 100. RESULTS: Vaccine effectiveness was 75% (adjusted odds ratio [AOR], 0.25; 95% confidence interval [CI], .16-.39) in preventing influenza outpatient cases, 60% (AOR, 0.40; 95% CI, .25-.63) in preventing influenza-associated hospitalizations, and 89% (AOR, 0.11; 95% CI, .04-.37) in preventing severe cases. In inpatients, influenza vaccination was associated with a lower risk of severe influenza (AOR, 0.42; 95% CI, .22-.80). CONCLUSIONS: Influenza vaccination prevented influenza cases and hospitalizations and was associated with a better prognosis in inpatients with influenza. The combined effect of these 2 mechanisms would explain the high effectiveness of the vaccine in preventing severe cases due to influenza.
Entities:
Keywords:
influenza vaccine; influenza virus; severe influenza; vaccine effectiveness
Authors: Joshua G Petrie; Caroline Cheng; Ryan E Malosh; Jeffrey J VanWormer; Brendan Flannery; Richard K Zimmerman; Manjusha Gaglani; Michael L Jackson; Jennifer P King; Mary Patricia Nowalk; Joyce Benoit; Anne Robertson; Swathi N Thaker; Arnold S Monto; Suzanne E Ohmit Journal: Clin Infect Dis Date: 2015-11-12 Impact factor: 9.079
Authors: Jill M Ferdinands; Manjusha Gaglani; Emily T Martin; Don Middleton; Arnold S Monto; Kempapura Murthy; Fernanda P Silveira; H Keipp Talbot; Richard Zimmerman; Elif Alyanak; Courtney Strickland; Sarah Spencer; Alicia M Fry Journal: J Infect Dis Date: 2019-09-13 Impact factor: 5.226
Authors: Carmen S Arriola; Evan J Anderson; Joan Baumbach; Nancy Bennett; Susan Bohm; Mary Hill; Mary Lou Lindegren; Krista Lung; James Meek; Elizabeth Mermel; Lisa Miller; Maya L Monroe; Craig Morin; Oluwakemi Oni; Arthur Reingold; William Schaffner; Ann Thomas; Shelley M Zansky; Lyn Finelli; Sandra S Chaves Journal: J Infect Dis Date: 2015-03-27 Impact factor: 5.226
Authors: Jelena Catania; Loretta G Que; Joseph A Govert; John W Hollingsworth; Cameron R Wolfe Journal: Am J Respir Crit Care Med Date: 2014-02-15 Impact factor: 21.405
Authors: Núria Torner; Ana Martínez; Luca Basile; M Angeles Marcos; Andrés Antón; M Mar Mosquera; Ricard Isanta; Carmen Cabezas; Mireia Jané; Angela Domínguez; The Pidirac Sentinel Surveillance Program Of Catalonia Journal: Hum Vaccin Immunother Date: 2014-11-01 Impact factor: 3.452